Ozempic for Weight Loss: Who Qualifies & Clinical Criteria

Last reviewed: May 18, 2026

Last updated: May 18, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic (semaglutide) can be prescribed for weight loss in patients meeting specific clinical criteria, though it was originally approved for type 2 diabetes. The FDA approved a higher-dose formulation called Wegovy for chronic weight management in 2021, expanding access for eligible candidates.

Determining whether you qualify involves more than BMI alone. Your provider evaluates metabolic health, cardiovascular risk factors, medication history, and individual response potential. Understanding these factors—and how your genetics may influence GLP-1 receptor signaling—supports a more informed and personalized treatment discussion.

FDA Approval Status and Weight Loss Indication

Semaglutide carries two FDA-approved pathways for weight management. Ozempic (1-2 mg weekly) is approved for type 2 diabetes; Wegovy (2.4 mg weekly) is specifically approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities.

Off-label prescribing of Ozempic for weight loss occurs when providers determine clinical benefit exceeds regulatory restriction. This requires documented medical necessity and informed patient consent. The distinction between on-label and off-label use affects insurance coverage and patient expectations.

Clinical Criteria for Ozempic Weight Loss Eligibility

Providers assess multiple factors beyond body mass index. Standard criteria include BMI ≥30 or ≥27 with weight-related conditions, established cardiovascular disease or risk factors, and absence of personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2.

Eligibility Factor	Clinical Threshold or Consideration
Body Mass Index	≥30 (or ≥27 with weight-related comorbidities like hypertension, sleep apnea)
Cardiovascular Status	Established CVD or multiple risk factors warrant closer monitoring; recent cardiac event may delay initiation
Thyroid/Endocrine History	Absolute contraindication: personal/family history of medullary thyroid cancer or MEN2
Kidney Function	Caution with eGFR <15; dose adjustment may be needed; provider monitoring essential
Pancreatitis History	Personal history requires careful risk-benefit assessment and informed consent
Medication Interactions	Assess sulfonylureas, insulin, and GLP-1 agonists for hypoglycemia risk and dosing changes

How Genetic Predispositions Inform Treatment Fit

Genetic variation in GLP-1 receptor signaling, FTO gene expression, and melanocortin-4 receptor pathways influences how individuals respond to semaglutide therapy. Two individuals with identical BMI may have different weight loss trajectories based on underlying biology.

The Precision Peptide Genetic Test identifies key variants (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, MC4R rs17782313) that may help provide context for individual predispositions in appetite regulation and metabolic response. This information should be interpreted with a qualified healthcare provider to support treatment selection discussions.

Medical Exclusions and Safety Considerations

Absolute contraindications include personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia type 2, and severe pancreatitis. Relative contraindications requiring careful evaluation include kidney disease, gastroparesis, and concurrent use of insulin or sulfonylureas due to hypoglycemia risk.

Pregnancy, planned pregnancy within six months, and active gastrointestinal disease warrant provider discussion. Semaglutide has demonstrated fetal risk in animal studies. Your healthcare team must weigh eligibility against individual medical complexity and monitor for side effects including nausea, dehydration, and rare but serious pancreatitis or gallbladder complications.

Compounded vs. Branded Formulations: What Patients Should Know

Branded semaglutide (Ozempic, Wegovy) and compounded semaglutide injections differ in manufacturing pathway and cost. Both contain the same active ingredient; compounded formulations from licensed 503A pharmacies offer lower out-of-pocket cost ($149 monthly) compared to branded options, which may exceed $900 without insurance.

Your provider can prescribe either formulation based on preference, insurance coverage, and availability. Compounded medications are not FDA-approved but are manufactured under strict pharmacy compounding standards. Discussing formulation options—compounded semaglutide injection, oral semaglutide, or compounded tirzepatide—with your provider ensures alignment with your clinical needs and budget.

How PlexusDx Supports a More Personalized Approach

PlexusDx believes that prescribing decisions benefit from understanding individual genetic context. Our Precision Peptide Genetic Test may help provide insights into GLP-1 receptor sensitivity and metabolic predispositions relevant to semaglutide response. This information can support a more personalized conversation with your provider about whether GLP-1 therapy aligns with your biology.

The test reveals predispositions in four key genetic pathways affecting appetite, energy expenditure, and GLP-1 signaling. Variants in GLP1R, GIPR, FTO, and MC4R genes may influence individual response potential. These predispositions do not predict exact medication response or guarantee outcomes; rather, they offer one data point within a comprehensive clinical assessment.

When combined with traditional eligibility criteria—BMI, cardiovascular status, kidney function, and medical history—genetic insights help contextualize treatment fit. Sharing test results with your provider supports an informed decision about whether compounded or branded semaglutide, tirzepatide, or alternative approaches best suit your individual health profile and goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.